Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561073 | 1.00 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL1272345 | 0.82 | GPR84 (0.56) | GPR84RAB9ASMN1; SMN2CA1TYMP | |
| SCHEMBL28903016 | 0.78 | MAPT (0.40) | GPR84RAB9ASMN1; SMN2MAPTTSHR | |
| SCHEMBL9220998 | 0.76 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL11844328 | 0.76 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL18018476 | 0.76 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL2959182 | 0.76 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL5508748 | 0.76 | GPR84 (0.50) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL5071203 | 0.76 | GPR84 (0.60) | GPR84RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL22851529 | 0.73 | GPR84 (0.47) | GPR84RAB9ASMN1; SMN2CA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-115947692-B | Method for preparing 2-chloro-4- (methoxymethyl) pyrimidine | 上海再启生物技术有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-115947692-A | Method for preparing 2-chloro-4- (methoxymethyl) pyrimidine | 上海再启生物技术有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-115785486-A | Preparation method of polyion liquid hydrogel with high tensile strength, toughness, rapid recovery and fatigue resistance | 黑龙江省科学院高技术研究院 | 2023-03-14 | — | — | CN | claimed |
| US-11465988-B2 | Process for the preparation of Tipiracil hydrochloride and intermediates thereof | NATCO PHARMA LIMITED (IN) | 2022-10-11 | — | — | US | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| US-20220056016-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2022-02-24 | — | — | US | claimed |
| CN-105367546-A | A preparing process of alogliptin benzoate | BEIJING DOCTORANTE TECH DEV CO LTD | 2016-03-02 | — | — | CN | claimed |
| CN-103980249-B | A kind of process for purification of SYR-322 | XINXING MEDICAMENT DEVELOPMENT CO., LTD., ANHUI PROV. (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-105017161-A | Compound, and preparation method and applications thereof | NANJING BIODEALPHARM CO LTD | 2015-11-04 | — | — | CN | claimed |
| CN-104592195-A | A preparing process of alogliptin benzoate | JIANGSU WANBANG BIOPHARMACEUTICALS CO LTD | 2015-05-06 | — | — | CN | claimed |
| CN-104402832-A | Preparation method of dihydropyrimidine derivative | GUANGDONG HEC PHARMACEUTICAL | 2015-03-11 | — | — | CN | claimed |
| CN-104311535-A | Method for preparing DPP-IV inhibitor | GUANGDONG HEC PHARMACEUTICAL | 2015-01-28 | — | — | CN | claimed |
| CN-104193726-A | Synthesis method of alogliptin benzoate | JIANGSU DEYUAN PHARMACEUTICAL CO LTD | 2014-12-10 | — | — | CN | claimed |
| CN-103980249-A | Method for refining alogliptin benzoate | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD | 2014-08-13 | — | — | CN | claimed |
| EP-0177574-B1 | AMINOCARNITINES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-12-20 | — | — | EP | claimed |
| US-4781863-A | FROM 6-CHLOROMETHYLURACIL | CORNELL RESEARCH FOUNDATION, INC. (US) | 1988-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056016-A1 | IMPROVED PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE AND INTERMEDIATES THEREOF | DHPS, MTHFD1, DHFR | GPR84 3918/4885RAB9A 1700/4885SMN1; SMN2 2445/4885 |
| US-11465988-B2 | Process for the preparation of Tipiracil hydrochloride and intermediates thereof | DHPS, MTHFD1, DPYD | GPR84 3847/4885RAB9A 1622/4885SMN1; SMN2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.